08:00 | Registration | |||
09:00 | Inauguration | |||
Plenary Session | ||||
09:15 |
| |||
10:15 | Coffee Break and Networking Session | |||
SESSION 1: Strategies in ADC Synthesis and Characterization/ Session Chair: Ajay Kumar Gupta | ||||
10:45 | Challenges and Opportunities in the Synthesis of Antibody Drug Conjugate Payloads In this presentation, process
chemistry including route design and process design will be discussed for
preparation of Antibody Drug Conjugates Payloads. Further, this talk will also
explain how principal component analysis can be used to analyse known lists of
available cytotoxic molecules which promotes the use of payloads that target
chemotherapeutic mechanisms as well as identifying those which are structurally
simple and commercially available. | |||
11:25 | Antibody Drug Conjugates towards a Novel Approach and their Characteristics for Efficient Cancer Therapeutics: Future Prospects and Challenges | |||
12:05 |
| |||
13:05 | Lunch Break and Networking Session | |||
SESSION 2: Designing Antibody Drug Conjugates/ Session Chair: Mark Wright | ||||
14:05 |
| |||
15:05 | Development of Antibody-BFCA Conjugates for Radioimmunotherapy of Cancer | |||
15:45 | Coffee Break and Networking Session | |||
16:15 | Incorporation of Homo-Bi-Functional Spacer via Hydrazone and Diimide Bond between Hapten-Protein Conjugate This talk will focus on development of
conjugation chemistry for production of conjugated molecules. It will
specifically describe coupling of hapten to protein through homo-bi-functional spacer via
hydrazone and diimide bond. Further, it will discuss the importance of the Incorporation of Labile Bond (hydrazone) in
ADC along with the strategy that may be adopted for generation of ADC. | |||
16:55 | Technology Spotlight: | |||
17:25 | End of First Day of Conference |
SESSION 3: Development and Manufacture of ADC/ Session Chair: Dimiter Dimitrov | ||
09:30 | Generation of an Optimal Antibody-Drug Conjugate for Oncology Therapy: Evolving Guiding Principles This presentation will discuss the principles
involved in generation of ADCs for Oncology Therapy. Further, it will focus on engineering and optimization of tumor targeting antibody vehicle,
conjugation strategy, and chemistry of linker-payload. Factors that guide the optimization
of antibody vehicle to suit the linker-payload and conjugation chemistry will
also be discussed. | |
10:10 | Smooth Antibody Drug Conjugate Development and Manufacturing This presentation will give an Overview of ADC manufacturing along with Process development
considerations for Cysteine and Lysine conjugations. Further, Case study
looking at the design and testing of ADC development candidates will be
discussed. | |
10:50 | Coffee Break and Networking Session | |
SESSION 4: Nanotechnology for Delivery of ADCs/ Session Chair: Jeremy Parker | ||
11:20 | Nanotheranostic Systems for Pancreatic Cancer: Therapeutic Potential and Challenges In
this presentation, different strategies for selective delivery of nano based chemotherapeutics
to pancreatic cancer site and simultaneous imaging (theranostics) will be
described. ADCs, siRNA and ligand receptor based multifunctional nanoconjugates
and their therapeutic potential against this deadly cancer will be discussed. The
other part of the discussion will be focused on the major challenges associated
with successful clinical translation of nanotheranostic systems and their
possible solutions for early diagnosis of cancers. | |
12:00 | Engineering of Antibody Conjugated Drug Loaded Nanoparticle for Targeted Drug Delivery In
this presentation, various selective targeting strategies using nanoparticles
for achieving effective cancer detection and treatment would be discussed.
Various targeting moieties which may be used as 'escort' molecules to specific
tumor tissues including peptides and antibodies etc would be discussed. In
addition, different methods of conjugating the functional moieties to nanoparticles
and strategies for optimizing the nanoparticle surfaces for in vivo applications would
be discussed. | |
12:40 | Lunch Break and Networking Session | |
SESSION 5: Approaches for Targeting ADCs | ||
13:40 | Site-Specific Antibody Drug Conjugation through Carbohydrate | |
14:10 | Use of Abrin-Antibody Conjugates in Cell-Targeted Killing | |
14:50 | Novel Drug Discovery on Antibody-Drug Conjugate System This talk will focus on how to develop a novel antibody-drug
conjugate system through expanding
genetic code and its superiority over other ADC systems. It will also
include strategies and approaches
for selecting an antibody,
linker, toxin/s and payload for the development of a novel ADC system from bench side to bedside for the treatment of
Her2+ breast cancer though strong collaboration between academia and
industries. | |
15:30 | Bioanalytical & Pre-Clinical Development Strategies for ADCs In this talk, development of trastuzumab-emtansine will be discussed as a case study. Further,
it will throw light on Product Development and Pre-Clinical Strategies for
ADCs. | |
16:00 | Coffee Break and Networking Session | |
Panel Discussion: Safety & Efficacy of Antibody Drug Conjugates- Where are We Currently? | ||
16:30 | Safety & Efficacy of Antibody Drug Conjugates- Where are We Currently? Ajay
Kumar Gupta, Senior Counsellor / Director & Head, Confederation of
Indian Industry, India Jeremy
Parker, Principal Scientist, AstraZeneca, United Kingdom Mark
Wright, Site Lead, Piramal Healthcare UK Ltd, United Kingdom | |
17:00 | End of Conference |